BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28820644)

  • 1. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
    Childers CP; Childers KK; Maggard-Gibbons M; Macinko J
    J Clin Oncol; 2017 Dec; 35(34):3800-3806. PubMed ID: 28820644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
    Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
    J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    Rodriguez-Velazquez A; Velez R; Lafontaine JC; Colon-Echevarria CB; Lamboy-Caraballo RD; Ramirez I; Mendoza A; Casbas-Hernandez P; Armaiz-Pena GN
    BMC Cancer; 2018 Nov; 18(1):1177. PubMed ID: 30482165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire.
    Hughes KS; Roche C; Campbell CT; Siegel N; Salisbury L; Chekos A; Katz MS; Edell E
    Breast J; 2003; 9(1):19-25. PubMed ID: 12558666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
    Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
    Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
    Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
    Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
    Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
    Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
    Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
    Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
    J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    Hull LE; Haas JS; Simon SR
    Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
    Knerr S; Bowles EJA; Leppig KA; Buist DSM; Gao H; Wernli KJ
    J Natl Cancer Inst; 2019 Aug; 111(8):795-802. PubMed ID: 30753636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
    Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast and ovarian cancer: review and future perspectives.
    Lux MP; Fasching PA; Beckmann MW
    J Mol Med (Berl); 2006 Jan; 84(1):16-28. PubMed ID: 16283147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.